Naveruclif (Paclitaxel)

Paclitaxel, the active ingredient in Naveruclif, is a Taxane presented as an intravenous formulation for use in oncology. It is employed in the treatment of several solid tumours, including breast, ovarian and non‑small cell lung cancers, by inhibiting cell division in malignant cells. The drug works by stabilizing microtubules, thereby preventing mitotic spindle formation and leading to tumor cell death.

GNH USA supplies Naveruclif as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Naveruclif is a taxane chemotherapy used to treat solid tumours in several cancer types.

- Breast cancer: used as part of combination regimens to control disease progression and improve survival. - Ovarian cancer: administered to reduce tumour burden and support surgical outcomes. - Non‑small cell lung cancer: employed to inhibit tumor growth within standard chemotherapy protocols.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss during treatment cycles. - Nausea and vomiting: gastrointestinal upset common with chemotherapy. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: can include anaphylaxis during infusion. - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Pulmonary toxicity: interstitial pneumonitis or acute respiratory distress. - Cardiac arrhythmias: irregular heart rhythms observed in some patients. - Severe mucositis: painful inflammation of the mouth and gastrointestinal lining.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for adverse events. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess for hypersensitivity: pre‑medicate and observe during infusion. - Evaluate liver function: adjust dosing if hepatic impairment is present. - Avoid use in patients with known hypersensitivity to taxanes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paclitaxel may interact with other drugs that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - CYP2C8 inhibitors (e.g., gemfibrozil): may raise paclitaxel plasma levels and toxicity. - Strong CYP3A4 inducers (e.g., rifampin): can reduce drug exposure and efficacy. - Concurrent myelosuppressive agents: increase risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Monoclonal antibodies (e.g., bevacizumab): may heighten infusion‑related reactions. - Anticoagulants: heightened bleeding risk due to thrombocytopenia.